Abiologics
Focus: Abiologics is a Cambridge-based biotech company specializing in Synteins, a novel therapeutic modality, with focus on Neurology and Infectious Diseases. Public-stage company founded in 2000 with limited disclosed scale metrics.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
3-1 this month
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Should You Work at Abiologics?
AI assessmentAbiologics offers scientific novelty in Synteins but presents execution risk due to opaque pipeline visibility and minimal hiring activity.
Why Work Here
- Established 24-year-old company with public status provides stability and capital access compared to early-stage startups
- Focused R&D hiring (3 of 4 active roles) signals active pipeline development in emerging Syntein modality
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Abiologics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.